Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.02, Bloomberg Earnings reports.
Shares of Marinus Pharmaceuticals (MRNS) traded up 5.60% on Wednesday, reaching $5.85. The company’s stock had a trading volume of 551,204 shares. The company’s market cap is $152.54 million. The firm has a 50 day moving average of $5.39 and a 200 day moving average of $2.70. Marinus Pharmaceuticals has a 52-week low of $0.82 and a 52-week high of $8.22.
COPYRIGHT VIOLATION NOTICE: “Marinus Pharmaceuticals, Inc. (MRNS) Announces Earnings Results, Beats Expectations By $0.02 EPS” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/11/01/marinus-pharmaceuticals-inc-mrns-announces-earnings-results-beats-expectations-by-0-02-eps.html.
A number of equities research analysts recently commented on MRNS shares. ValuEngine lowered Marinus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 13th. JMP Securities reiterated an “outperform” rating and issued a $11.00 price objective (up from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 12th.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
What are top analysts saying about Marinus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Marinus Pharmaceuticals Inc. and related companies.